Skip to content
  • About
    • Company Overview
    • Milestones
    • Board of Directors
    • Management Team
    • Organization Chart
    • CSR
  • Pipeline
    • Globo H
      • Adagloxad simolenin (Vaccine)
      • OBI-833 (Vaccine)
      • OBI-888 (mAb)
      • OBI-999 (ADC)
    • SSEA-4
      • OBI-866 (Vaccine)
    • AKR1C3
      • OBI-3424 (Prodrug)
    • Others
      • OBI-858 (Botulinum toxin)
  • News
    • News
    • Company Presentation
  • Investors
    • Investor Overview
    • About
      • Company Profile
      • Corporate Governance
      • Stakeholder
    • News&Events
      • Announcements
      • Event Calendar
    • Financial Information
      • Annual Report
      • Financial Report​
      • Monthly Revenues
      • Stock Quote
  • Careers
  • Contact
  • 繁體中文
  • About
    • Company Overview
    • Milestones
    • Board of Directors
    • Management Team
    • Organization Chart
    • CSR
  • Pipeline
    • Globo H
      • Adagloxad simolenin (Vaccine)
      • OBI-833 (Vaccine)
      • OBI-888 (mAb)
      • OBI-999 (ADC)
    • SSEA-4
      • OBI-866 (Vaccine)
    • AKR1C3
      • OBI-3424 (Prodrug)
    • Others
      • OBI-858 (Botulinum toxin)
  • News
    • News
    • Company Presentation
  • Investors
    • Investor Overview
    • About
      • Company Profile
      • Corporate Governance
      • Stakeholder
    • News&Events
      • Announcements
      • Event Calendar
    • Financial Information
      • Annual Report
      • Financial Report​
      • Monthly Revenues
      • Stock Quote
  • Careers
  • Contact
  • 繁體中文

Investor Overview

Announcements

Date

Title

2021/02/17

OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, Adagloxad Simolenin, to the drug administrations in Argentina, Brazil, and South Africa

2020/01/26

Mr. Michael Chang and five other executives received an acquittal for insider trading case at second instance by Taiwan High Court

Read More

Annual Report

2019Annual Report  (PDF)

2018Annual Report (PDF)

See More

Financial Report

2020Financial Report Q1

2019Financial Report Q1

See More

Stock Quote

See More

Event Calendar

See More

Monthly Revenues

See More
Corporate Governance
Read More
Stakeholder
Read More

Company Profile

Read More

Company Overview

Management Team

CSR

Pipeline

News

Investors Overview

Careers

Contact

© 2020 OBI Pharma.Web Development by 展躍設計

We use cookies to improve your user experience and for web traffic statistics purposes. By continuing to use this website, you agree to our use of cookies.
Cookie SettingsAccept
Manage consent
Required
Always Enabled

Required Cookies is very important on website, including security and functionality. The Cookies doesn't collect your personal information.

Not required

All Cookies required are used. Not required Cookies for collecting personal info, data and advertising.

  •  

  •